MX2019012871A - Variantes de proteina morfogenica osea humana 7 (bmp7). - Google Patents

Variantes de proteina morfogenica osea humana 7 (bmp7).

Info

Publication number
MX2019012871A
MX2019012871A MX2019012871A MX2019012871A MX2019012871A MX 2019012871 A MX2019012871 A MX 2019012871A MX 2019012871 A MX2019012871 A MX 2019012871A MX 2019012871 A MX2019012871 A MX 2019012871A MX 2019012871 A MX2019012871 A MX 2019012871A
Authority
MX
Mexico
Prior art keywords
variants
human bmp7
bmp7 protein
protein
human
Prior art date
Application number
MX2019012871A
Other languages
English (en)
Inventor
Louis Frank Stancato
James David Pancook
Scott William Rowlinson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019012871A publication Critical patent/MX2019012871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2857—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a variantes novedosas de la proteína BMP7 humana. La invención incorpora vectores y células hospederas para la propagación de secuencias de ácido nucleico que codifican las proteínas y la producción de las mismas. También se describen métodos para el tratamiento de cáncer, daño y degeneración de cartílago, dolor asociado con osteoartritis, o curación ósea.
MX2019012871A 2017-04-27 2018-04-20 Variantes de proteina morfogenica osea humana 7 (bmp7). MX2019012871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762490910P 2017-04-27 2017-04-27
PCT/US2018/028496 WO2018200322A1 (en) 2017-04-27 2018-04-20 Variants of human bmp7 protein

Publications (1)

Publication Number Publication Date
MX2019012871A true MX2019012871A (es) 2021-01-08

Family

ID=62196685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012871A MX2019012871A (es) 2017-04-27 2018-04-20 Variantes de proteina morfogenica osea humana 7 (bmp7).

Country Status (17)

Country Link
US (1) US11466066B2 (es)
EP (1) EP3615561B1 (es)
JP (1) JP7308151B2 (es)
KR (1) KR20200012870A (es)
CN (1) CN110997708A (es)
AU (1) AU2018258100B2 (es)
BR (1) BR112019022566A2 (es)
CA (1) CA3061606A1 (es)
CL (1) CL2019003074A1 (es)
CO (1) CO2019013150A2 (es)
CR (1) CR20190539A (es)
EA (1) EA201992558A1 (es)
MX (1) MX2019012871A (es)
PE (1) PE20200385A1 (es)
PH (1) PH12019502442A1 (es)
SG (1) SG11201910009UA (es)
WO (1) WO2018200322A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552425A1 (en) * 2019-03-29 2022-07-11 Kolon Tissuegene Inc Mixed-cell gene therapy
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
WO2022271466A1 (en) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
KR20230003879A (ko) 2021-06-30 2023-01-06 현대자동차주식회사 하이브리드 차량의 림프홈 후진 주행 제어 시스템 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561809A1 (en) 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
AU2007339280B2 (en) 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
WO2008151258A2 (en) * 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
US7846428B2 (en) * 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
JP5529754B2 (ja) 2007-12-21 2014-06-25 ストライカー コーポレイション Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体

Also Published As

Publication number Publication date
CR20190539A (es) 2020-03-26
US11466066B2 (en) 2022-10-11
CA3061606A1 (en) 2018-11-01
JP7308151B2 (ja) 2023-07-13
EA201992558A1 (ru) 2020-03-04
US20210115100A1 (en) 2021-04-22
CO2019013150A2 (es) 2020-02-28
CN110997708A (zh) 2020-04-10
AU2018258100B2 (en) 2022-04-14
CL2019003074A1 (es) 2020-05-08
AU2018258100A1 (en) 2019-11-14
SG11201910009UA (en) 2019-11-28
KR20200012870A (ko) 2020-02-05
PE20200385A1 (es) 2020-02-24
EP3615561B1 (en) 2024-01-10
BR112019022566A2 (pt) 2020-05-19
WO2018200322A1 (en) 2018-11-01
PH12019502442A1 (en) 2020-10-05
EP3615561C0 (en) 2024-01-10
JP2020517706A (ja) 2020-06-18
EP3615561A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX395421B (es) Moleculas de acido nucleico artificiales.
PH12019502442A1 (en) Variants of human bmp7 protein
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2025003310A (es) Integracion dirigida de acidos nucleicos
WO2017077329A3 (en) Nucleic acids, peptides and methods
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
BR112022006842A2 (pt) Construtos de igf2 variante
PH12019500571A1 (en) Anti-pd-1 antibodies
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX351565B (es) Colageno 7 y metodos relacionados.
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
WO2018132821A3 (en) Elastomeric proteins
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
BR112015019719A2 (pt) Proteínas melhoradas de ligação ao tnf
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
WO2016160976A3 (en) Monovalent tnf binding proteins